文献速递头颈神经MR

基于影像组学的列线图指导局部晚期鼻咽癌诱导化疗后的适应性降强度治疗

Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy.
PubMed 文献 · Eur Radiol · 2024-03-22

该回顾性研究纳入718例接受诱导化疗后调强放疗或同步放化疗的局部晚期鼻咽癌患者,利用诱导化疗前后MRI提取影像组学特征构建列线图。列线图在训练集和验证集的AUC分别为0.80和0.75,可区分高低危人群;高危患者接受同步放化疗预后更优,低危患者两种方案预后相当,提示低危患者或可考虑省略同步化疗。

要点

  • 基于诱导化疗前后MRI的Δ影像组学特征联合临床指标构建列线图,可预测局部晚期鼻咽癌预后及同步化疗获益。
  • 列线图区分的高低危组总生存差异显著;高危组同步放化疗优于单纯调强放疗,低危组两者相当。
  • 列线图定义的低危患者可能是省略同步化疗的潜在候选人群。

核心结论

  • 基于影像组学的列线图可预测局部晚期鼻咽癌诱导化疗后的预后及同步化疗生存获益,列线图定义的低危患者可能是调强放疗期间省略同步化疗的潜在候选人群。

研究设计与样本

  • 回顾性队列研究,纳入718例接受诱导化疗+调强放疗或诱导化疗+同步放化疗的局部晚期鼻咽癌患者,分为训练集503例和验证集215例;从诱导化疗前和诱导化疗后MRI提取影像组学特征,采用LASSO-Cox回归构建Δ影像组学标签,并联合独立临床指标构建列线图。

关键影像表现/征象

  • Δ影像组学标签由19个 selected 特征组成,与预后独立相关。

诊断标准与关键数值

  • 列线图包含Δ影像组学标签、年龄、T分期、N分期、治疗方式和治疗前EBV DNA。
  • 列线图在训练集和验证集的AUC分别为0.80(95%CI 0.75-0.85)和0.75(95%CI 0.64-0.85)。
  • 排除治疗因素后的列线图风险分层可将患者分为总生存不同的两组。

临床应用与阅片要点

  • 高危患者接受诱导化疗+同步放化疗的预后显著优于诱导化疗+调强放疗,低危患者两种方案预后相当。
  • 作者认为,列线图定义的低危患者可能是调强放疗期间省略同步化疗的潜在候选人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to construct a radiomics-based model for prognosis and benefit prediction of concurrent chemoradiotherapy (CCRT) versus intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) following induction chemotherapy (IC).

MATERIALS AND METHODS: A cohort of 718 LANPC patients treated with IC + IMRT or IC + CCRT were retrospectively enrolled and assigned to a training set (n = 503) and a validation set (n = 215). Radiomic features were extracted from pre-IC and post-IC MRI. After feature selection, a delta-radiomics signature was built with LASSO-Cox regression. A nomogram incorporating independent clinical indicators and the delta-radiomics signature was then developed and evaluated for calibration and discrimination. Risk stratification by the nomogram was evaluated with Kaplan-Meier methods.

RESULTS: The delta-radiomics signature, which comprised 19 selected features, was independently associated with prognosis. The nomogram, composed of the delta-radiomics signature, age, T category, N category, treatment, and pre-treatment EBV DNA, showed great calibration and discrimination with an area under the receiver operator characteristic curve of 0.80 (95% CI 0.75-0.85) and 0.75 (95% CI 0.64-0.85) in the training and validation sets. Risk stratification by the nomogram, excluding the treatment factor, resulted in two groups with distinct overall survival. Significantly better outcomes were observed in the high-risk patients with IC + CCRT compared to those with IC + IMRT, while comparable outcomes between IC + IMRT and IC + CCRT were shown for low-risk patients.

CONCLUSION: The radiomics-based nomogram can predict prognosis and survival benefits from concurrent chemotherapy for LANPC following IC. Low-risk patients determined by the nomogram may be potential candidates for omitting concurrent chemotherapy during IMRT.

CLINICAL RELEVANCE STATEMENT: The radiomics-based nomogram was constructed for risk stratification and patient selection. It can help guide clinical decision-making for patients with locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy, and avoid unnecessary toxicity caused by overtreatment.

KEY POINTS: • The benefits from concurrent chemotherapy remained controversial for locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy. • Radiomics-based nomogram achieved prognosis and benefits prediction of concurrent chemotherapy. • Low-risk patients defined by the nomogram were candidates for de-intensification.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang SX, Yang Y, Xie H, et al. Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy. Eur Radiol. 2024. PMID: 38514481. doi:10.1007/s00330-024-10678-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。